Source: Urology Times
The News Review:
- Source: Urology Times
- Source: Urology Times
- Source: Urology Times
- Source: Urology Times
- As we enter 2009 are you optimistic or pessimistic about urology …
- NYMX: Successful Trial Results for NX-1207 Published in The …
- FDA Approves Ferring Pharmaceuticals’ Degarelix (Generic Name) for …
Source: Urology Times
Modern Medicine NJ
MoreyDallas—Perirenal hematoma characteristics determined by computed tomography may be suggestive of the need for angiographic embolization in patients who present with blunt renal trauma a study from the University of Texas Southwestern Medical Center Dallas suggests. “The size of the hematoma is a new way of looking at these injuries” said senior author Allen F. Morey MD professor of urology at UT Southwestern. “Traditional staging calls for evaluating renal injuries in terms of the depth of the injury and involvement of the collecting system. The magnitude of perirenal hematoma also appears to be an important radiographic feature. “We noted a trend toward increased use of computed tomography in evaluating trauma patients.
Source: Urology Times
Modern Medicine NJ
That was the key message from a review presented at the American College of Surgeons Clinical Congress here. A retrospective evaluation of 50 robot-assisted laparoscopic radical cystectomies performed at the University of North Carolina at Chapel Hill found that the robotic procedure offers perioperative outcomes similar to those of more traditional cystectomies and similar oncologic outcomes in the medium term. “Robot-assisted laparoscopy has emerged as a viable alternative to other techniques” said first author Matthew Pearson MD a urology resident at the University of North Carolina working under the direction of Raj S. “This series of procedures shows robotic cystectomy to be technically feasible with acceptable medium-term oncologic outcomes but we need longer follow-up before making a positive recommendation. ” A robot-assisted procedure offers better optics and finer technical control than a manual laparoscopic procedure does. ther potential benefits include reduced intraoperative blood loss decreased fluid shifts less postoperative pain and less bowel manipulation than with the manual procedure Dr.
Source: Urology Times
Modern Medicine NJ
BCG decreases recurrence and progression of bladder cancer by inducing nonspecific cystitis through multiple pathways that are mediated by TH1 cells. Skolarus now a urologic oncology fellow at the University of Michigan Ann Arbor led one of the first trials designed specifically to examine a possible association between statin use and intravesical BCG outcomes in VA patients with non-muscle-invasive bladder cancer. A pilot retrospective study followed 91 patients with a diagnosis of bladder cancer or carcinoma in situ who received intravesical BCG therapy. Patients had to receive at least three BCG treatments and could be taking any statin during the intravesical treatment period. “The patents were all male and mostly smokers as you would expect in an older VA population” Dr.
Source: Urology Times
Modern Medicine NJ
ne of the protesting companies Atlanta-based PRG-Schultz International Inc. claims CMS denied it a permanent contract because of its high contingency fee bid. PRG-Schultz conducted audits in California including those of several urology practices during the 3-year pilot program (see “California LHRH case holds lessons for all urologists” at.
As we enter 2009 are you optimistic or pessimistic about urology …
Modern Medicine NJ
ur politics are local. Eighteen million people in the Los Angeles area need medical care. If you can’t pee it’s an emergency. People will get treated even if insurance goes away.
NYMX: Successful Trial Results for NX-1207 Published in The …
Trading Markets (press release) CA
The Urology Times article entitled “Investigational benign prostatic hyperplasia drug improves urgency frequency” refers to the 47% reduction in symptoms of urgency and 43% improvement in the frequency of urination both of which were largely maintained for one year after a single treatment with NX-1207. KNBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer nor investment advisor and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein.
Related from Weightlossmonster: Arena announces obesity drug study results
FDA Approves Ferring Pharmaceuticals’ Degarelix (Generic Name) for …
PR Newswire (press release) NY
Pascal Danglas Executive Vice President Clinical & Product Development at Ferring. “We are delighted to deliver a new treatment option for advanced prostate cancer to the medical community. Ferring has a considerable pipeline of urology products in development and we expect to introduce additional treatment advances in the urology field in the near future. “Use of a GnRH receptor antagonist is a highly efficient way to stop the production of testosterone” said Neal Shore MD FACS Medical Director for Carolina Urologic Research Center a clinical trial investigator and advisor to Ferring. “The approval of degarelix offers the medical community an effective alternative in the treatment of hormonally-sensitive prostate cancer. Now prostate cancer can be treated with immediate inhibition of the GnRH receptors inducing rapid reduction of testosterone to castrate levels and sustaining those levels over time which are the goals of systemic therapy. When a patient has disease recurrence it is always encouraging to clinicians and patients to see PSA levels fall so rapidly.
Written by admin on December 25th, 2008 with
no comments.
Read more articles on News.